Inactive Instrument

News AbbVie Euronext Paris

Equities

ABBV

US00287Y1091

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	03:10pm	AQ
AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference	03/06	PR
Sector Update: Health Care Stocks Flat to Higher Pre-Bell Friday	31/05	MT
AbbVie Receives European Medicine Agency Committee's Recommendation for Approval of Severe Bowel Disease Drug Candidate	31/05	MT
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	31/05	PR
AbbVie Receives Positive CHMP Opinion for Risankizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis	31/05	CI
OSE Immuno: towards an evolution of the Board of Directors	30/05	CF
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results	29/05	AQ
AbbVie Completes Acquisition of Landos Biopharma	24/05	MT
AbbVie Inc. completed the acquisition of Landos Biopharma, Inc. from a group of shareholders.	23/05	CI
Strides Pharma Arm Gets US FDA's Approval for Generic Stomach Ulcer Drug	22/05	MT
BaseLaunch announced that it has received funding from AbbVie Inc.	22/05	CI
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	21/05	AQ
AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week	20/05	AQ
Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target	17/05	MT
ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta...	17/05
Transcript : AbbVie Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM	15/05
Medincell: share price falls after disappointing clinical study	15/05	CF
AbbVie, Gilgamesh Pharmaceuticals Partner to Develop Therapies for Psychiatric Disorders	13/05	MT
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders	13/05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AbbVie Euronext Paris

Equities

ABBV

US00287Y1091

Summary

Filters